“Women Innovators” Prize in the leading category of the European Prize for Women Innovators program was awarded to RS Research Co-Founder Prof. Rana Sanyal for her successful work in the field of biotechnology. […]
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as “The Home of Phase I in Oncology”. […]
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology (ESMO) 2022 Congress to be held in person on 9-13 September […]
Designing drug candidates with a superior therapeutic index, RS Research will advance to the next dose cohort following the positive review of the safety data from the dosing of the first cohort by the Independent Data Monitoring Committee (IDMC). Medical experts of IDMC recommended […]
RS Research announced that the first patient has been dosed in the Phase I clinical trial evaluating the safety of RS-0139 in NSCLC. RS Research’s pipeline is based on the proprietary platform technology SagittaTM, which are nanocarriers with versatile targeting capability and suitable […]
Clinical-stage biotechnology start-up developing smart nanomedicines in oncology raised $12 Million at Series-A Round with investors GEN, OneLife and Eczacıbaşı Momentum. This funding will help the company gain speed in the clinical development of its portfolio as well as become […]
RS Research was named one of the “5 Top Nanomedicine Startups Impacting The Healthcare Industry” by StartUs Insights
Technology focused venture capital fund ACT Venture Partners, whose main investor is European Investment Fund, has invested 1.1 million Euros in nanomedicine start-up RS Research. The company began developing drug candidates with improved efficacy and reduced side effect […]
